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Abstract
Mid-study design modifications are becoming increasingly accepted in confirmatory clinical trials,
so long as appropriate methods are applied such that error rates are controlled. It is therefore
unfortunate that the important case of time-to-event endpoints is not easily handled by the stan-
dard theory. We analyze current methods that allow design modifications to be based on the full
interim data, i.e., not only the observed event times but also secondary endpoint and safety data
from patients who are yet to have an event. We show that the final test statistic may ignore a
substantial subset of the observed event times. Since it is the data corresponding to the earliest
recruited patients that is ignored, this neglect becomes egregious when there is specific interest in
learning about long-term survival. An alternative test incorporating all event times is proposed,
where a conservative assumption is made in order to guarantee type I error control. We examine
the properties of our proposed approach using the example of a clinical trial comparing two cancer
therapies.
Keywords: Adaptive design; Brownian motion; Clinical trial; Combination test; Sample size
reassessment; Time-to-event.
1 Introduction
There are often strong ethical and economic arguments for conducting interim analyses of an
ongoing clinical trial and for making changes to the design if warranted by the accumulating
data. One may decide, for example, to increase the sample size on the basis of promising interim
results. Or perhaps one might wish to drop a treatment from a multi-arm study on the basis of
unsatisfactory safety data. Owing to the complexity of clinical drug development, it is not always
possible to anticipate the need for such modifications, and therefore not all contingencies can be
dealt with in the statistical design.
Unforeseen interim modifications complicate the (frequentist) statistical analysis of the trial con-
siderably. Over recent decades many authors have investigated so-called “adaptive designs” in
an effort to maintain the concept of type I error control (Bauer and Ko¨hne, 1994; Proschan and
Hunsberger, 1995; Mu¨ller and Scha¨fer, 2001; Hommel, 2001). Although Bayesian adaptive meth-
ods are becoming increasing popular, type I error control is still deemed important in the setting
of a confirmatory phase III trial (Berry et al., 2010, p. 6), and recent years have seen hybrid
adaptive designs proposed, whereby the interim decision is based on Bayesian methods, but the
final hypothesis test remains frequentist (Brannath et al., 2009; Di Scala and Glimm, 2011).
While the theory of adaptive designs is now well understood if responses are observed immediately,
subtle problems arise when responses are delayed, e.g., in survival trials.
Scha¨fer and Mu¨ller (2001) proposed adaptive survival tests that are constructed using the inde-
pendent increments property of logrank test statistics (c.f., Wassmer, 2006; Desseaux and Porcher,
2007; Jahn-Eimermacher and Ingel, 2009). However, as pointed out by Bauer and Posch (2004),
these methods only work if interim decision making is based solely on the interim logrank test
statistics and any secondary endpoint data from patients who have already had an event. In other
words, investigators must remain blind to the data from patients who are censored at the interim
analysis. Irle and Scha¨fer (2012) argue that decisions regarding interim design modifications should
be as substantiated as possible, and propose a test procedure that allows investigators to use the
full interim data. This methodology, similar to that of Jenkins et al. (2011), does not require any
assumptions regarding the joint distribution of survival times and short-term secondary endpoints,
as do, e.g., the methods proposed by Stallard (2010), Friede et al. (2011, 2012) and Hampson and
Jennison (2013).
The first goal of this article is to clarify the proposals of Jenkins et al. (2011) and Irle and Scha¨fer
(2012), showing that they are both based on weighted inverse-normal test statistics (Lehmacher
and Wassmer, 1999), with the common disadvantage that the final test statistic may ignore a
substantial subset of the observed survival times. This is a serious limitation, as disregarding part
of the observed data is generally considered inappropriate even if statistical error probabilities are
controlled – see, for example, the discussion on overrunning in group sequential trials (Hampson
and Jennison, 2013). Our secondary goal is therefore to propose an alternative test that retains
the strict type I error control and flexibility of the aforementioned designs, but bases the final test
decision on a statistic that takes into account all available survival times. As ever, there is no
free lunch, and the assumption that we require to ensure type I error control induces a certain
amount of conservatism. We evaluate the properties of our proposed approach using the example
of a clinical trial comparing two cancer therapies.
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2 Adaptive Designs
2.1 Standard theory
A comprehensive account of adaptive design methodology can be found in Bretz et al. (2009). For
testing a null hypothesis, H0 : θ = 0, against the one-sided alternative, Ha : θ > 0, the archetypal
two-stage adaptive test statistic is of the form f1(p1) +f2(p2), where p1 is the p-value based on the
first-stage data, p2 is the p-value from the (possibly adapted) second-stage test, and f1 and f2 are
prespecified monotonically decreasing functions. Consider the simplest case that no early rejection
of the null hypothesis is possible at the end of the first stage. The null hypothesis is rejected at
level α whenever f1(p1) + f2(p2) > k, where k satisfies∫ 1
0
∫ 1
0
1 {f1(p1) + f2(p2) ≤ k} dp1 dp2 = 1− α.
In their seminal paper, Bauer and Ko¨hne (1994) took fi(pi) = − log(pi) for i = 1, 2. We will
restrict attention to the weighted inverse-normal test statistic (Lehmacher and Wassmer, 1999),
Z = w1Φ
−1(1− p1) + w2Φ−1(1− p2), (1)
where Φ denotes the standard normal distribution function and w1 and w2 are prespecified weights
such that w21 + w
2
2 = 1. If Z > Φ
−1(1− α), then H0 may be rejected at level α. The assumptions
required to make this a valid level-α test are as follows (see Brannath et al., 2012).
Assumption 1
Let X int1 denote the data available at the interim analysis, where X
int
1 ∈ Rn with distribution
function G(xint1 ; θ). The calendar time of the interim analysis will be denoted T
int. In general,
X int1 will contain information not only concerning the primary endpoint, but also measurements
on secondary endpoints and safety data. It is assumed that the first-stage p-value function p1 :
Rn → [0, 1] satisfies ∫
Rn
1
{
p1(x
int
1 ) ≤ u
}
dG(xint1 ; 0) ≤ u for all u ∈ [0, 1] .
Assumption 2
At the interim analysis, a second-stage design d is chosen. The second-stage design is allowed to
depend on the unblinded first-stage data without prespecifying an adaptation rule. Denote the
second-stage data by Y , where Y ∈ Rm. It is assumed that the distribution function of Y , denoted
by Fd,xint1 (y, θ), is known for all possible second stage designs, d, and all first-stage outcomes, x
int
1 .
Assumption 3
The second-stage p-value function p2 : Rm → [0, 1] satisfies
∫
Rm 1 {p2(y) ≤ u} dFd,xint1 (y; 0) ≤
u for all u ∈ [0, 1].
2.2 Immediate responses
The aforementioned assumptions are easy to justify when primary endpoint responses are observed
more-or-less immediately. In this case X int1 contains the responses of all patients recruited prior to
the interim analysis. A second-stage design d can subsequently be chosen with the responses from
a new cohort of patients contributing to Y (Figure 1).
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Figure 1: Schematic of a standard two-stage adaptive trial with immediate response.
2.3 Delayed responses and the independent increments assumption
An interim analysis may take place whilst some patients have entered the study but have yet
to provide a data point on the primary outcome measure. Most approaches to this problem
(e.g., Scha¨fer and Mu¨ller, 2001; Wassmer, 2006; Jahn-Eimermacher and Ingel, 2009) attempt to
take advantage of the well known independent increments structure of score statistics in group
sequential designs (Jennison and Turnbull, 2000). As pictured in Figure 2, X int1 will generally
include responses on short-term secondary endpoints and safety data from patients who are yet
to provide a primary outcome measure, while Y consists of some delayed responses from patients
recruited prior to T int, mixed together with responses from a new cohort of patients.
Let S(X int1 ) and I(X int1 ) denote the score statistic and Fisher’s information for θ, calculated from
primary endpoint responses in X int1 . Assuming suitable regularity conditions, the asymptotic null
distribution of S(X int1 ) is Gaussian with mean zero and variance I(X int1 ) (Cox and Hinkley, 1979,
p. 107). The independent increments assumption is that for all first-stage outcomes xint1 and
second-stage designs d, the null distribution of Y is such that
S(xint1 , Y )− S(xint1 ) ∼ N
{
0, I(xint1 , Y )− I(xint1 )
}
, (2)
at least approximately, where SXint1 ,Y and IXint1 ,Y denote the score statistic and Fisher’s information
for θ, calculated from primary endpoint responses in (X int1 , Y ).
Unfortunately, (2) is seldom realistic in an adaptive setting. Bauer and Posch (2004) show that if
the adaptive strategy at the interim analysis is dependent on short-term outcomes in X int1 that are
correlated with primary endpoint outcomes in Y , i.e., from the same patient, then a naive appeal
to the independent increments assumption can lead to very large type I error inflation.
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Figure 2: Schematic of a two-stage adaptive trial with delayed response under the independent
increments assumption.
2.4 Delayed responses with “patient-wise separation”
An alternative approach, which we shall coin “patient-wise separation”, redefines the first-stage
p-value, p1 : Rp → [0, 1], to be a function of X1, where X1 denotes all the data from patients
recruited prior to T int, followed-up until calendar time Tmax – which corresponds to the prefixed
maximum duration of the trial. It is assumed that X1 takes values in Rp according to distribution
function G˜(x1; θ). Assumption 1 is replaced with:∫
Rp
1{p1(x1) ≤ u} dG˜(x1; 0) ≤ u for all u ∈ [0, 1] . (3)
In this case p1 may not be observable at the time the second-stage design d is chosen. This is
not a problem, as long as no early rejection at the end of the first stage is foreseen. Any interim
decisions, such as increasing the sample size, do not require any knowledge of p1. It is assumed that
Y consists of responses from a new cohort of patients, such that xint1 could be formally replaced
with x1 in assumptions 2 and 3. We call this “patient-wise separation” because data from the
same patient cannot contribute to both p1 and p2.
Liu and Pledger (2005) consider such an approach for a clinical trial where a patient’s primary
outcome is measured after a fixed period of follow-up, e.g., 4 months. Provided that one is willing
to wait for all responses, it is straightforward to prespecify a first-stage p-value function such that
(3) holds.
For an adaptive trial with a time-to-event endpoint, however, one must be very careful to ensure
that (3) holds, as one is typically not prepared to wait for all first-stage patients – those patients
recruited prior to T int – to have an event. Rather, p1 is defined as the p-value from an, e.g., logrank
test applied to the data from first-stage patients followed up until time T1, for some T1 < T
max. In
this case it is vital that T1 be fixed at the start of the trial, either explicitly or implicitly (Jenkins
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et al., 2011; Irle and Scha¨fer, 2012). Otherwise, if T1 were to depend on the adaptive strategy
at the interim analysis, this would impact the distribution of p1 and could lead to type I error
inflation.
The situation is represented pictorially in Figure 3. An unfortunate consequence of prefixing T1 is
that this will not, in all likelihood, correspond to the end of follow-up for second-stage patients.
All events of first-stage patients that occur after T1 make no contribution to the statistic (1); they
are “thrown away”.
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Figure 3: Schematic of a two-stage adaptive trial with “patient-wise separation”.
3 Adaptive Survival Studies
3.1 Jenkins et al. (2011) method
Consider a randomized clinical trial comparing survival times on an experimental treatment, E,
with those on a control treatment, C. We will focus on the logrank statistic for testing the null
hypothesis H0 : θ = 0 against the one-sided alternative Ha : θ > 0, where θ is the log hazard ratio,
assuming proportional hazards. Let D1(t) and S1(t) denote the number of uncensored events and
the usual logrank score statistic, respectively, based on the data from first-stage patients – those
patients recruited prior to the interim analysis – followed up until calendar time t, t ∈ [0, Tmax].
Under the null hypothesis, assuming equal allocation and a large number of events, the variance
of S1(t) is approximately equal to D1(t)/4 (e.g., Whitehead, 1997, Section 3.4). The first-stage
p-value must be calculated at a prefixed time point T1:
p1 = 1− Φ
[
2 {S1(T1)} / {D1(T1)}1/2
]
. (4)
There are two possible ways of specifying T1 in (4). From a practical perspective, a calendar time
approach is often attractive as T1 is specified explicitly, which facilitates straightforward planning.
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On the other hand, this can produce a misspowered study if the recruitment rate and/or survival
times differ markedly from those anticipated. An event driven approach may be preferred, whereby
the number of events is prefixed at d1, say, and
T1 := min {t : D1(t) = d1} . (5)
Jenkins et al. (2011) describe a “patient-wise separation” adaptive survival trial, with test statistic
(1), first-stage p-value (4) and T1 defined as in (5). While their focus is on subgroup selection,
we will appropriate their method for the simpler situation of a single comparison, where at the
interim analysis one has the possibility to alter the pre-planned number of events from second-stage
patients – i.e., those patients recruited post T int. All that remains to be specified at the design
stage is the choice of weights w1 and w2. It is anticipated that p2 will be the p-value corresponding
to a logrank test based on second-stage patients, i.e.,
p2 = 1− Φ
[
2S2(T
∗
2 )/ {D2(T ∗2 )}1/2
]
,
where T ∗2 := min {t : D2(t) = d∗2} with S2(t) and D2(t) defined analogously to S1(t) and D1(t),
and d∗2 is to be specified at the interim analysis. Ideally, the weights should be chosen in pro-
portion to the information (number of events) contributed from each stage. In an adaptive trial,
it is impossible to achieve the correct weighting in every scenario. Jenkins et al. prespecify the
envisioned number of second-stage events, d2, and choose weights w1 = {d1/(d1 + d2)}1/2 and
w2 = {d2/(d1 + d2)}1/2.
3.2 Irle and Scha¨fer (2012) method
Irle and Scha¨fer (2012) propose an alternative procedure. Instead of explicitly combining stage-wise
p-values, they employ the closely related conditional error approach (Proschan and Hunsberger,
1995; Posch and Bauer, 1999; Mu¨ller and Scha¨fer, 2001).
They begin by prespecifying a level-α test with decision function, ϕ, taking values in {0, 1} cor-
responding to nonrejection and rejection of H0, respectively. For a survival trial, this entails
specifying the sample size, duration of follow-up, test statistic, recruitment rate, etc. Then, at
some (not necessarily prespecified) timepoint, T int, an interim analysis is performed. The timing
of the interim analysis induces a partition of the trial data, (X1, X2), where X1 and X2 denote the
data from patients recruited prior- T int and post- T int, respectively, followed-up until time Tmax.
More specifically, Irle and Scha¨fer (2012) suggest the decision function
ϕ(X1, X2) = 1
[
2S1,2(T1,2)/ {D1,2(T1,2)}1/2 > Φ−1(1− α)
]
, (6)
where D1,2(T1,2) and S1,2(T1,2) denote the number of uncensored events and the usual logrank score
statistic, respectively, based on data from all patients (from both stages) followed-up until time
T1,2, where T1,2 := min {t : D1,2(t) = d1,2} for some prespecified number of events d1,2.
At the interim analysis, the general idea is to use the unblinded first-stage data xint1 to define
a second-stage design, d, without the need for a prespecified adaptation strategy. Again, the
definition of d includes factors such as sample size, follow-up period, recruitment rate, etc., in
addition to a second-stage decision function ψxint1 : R
m → {0, 1} based on second-stage data
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Y ∈ Rm. Irle and Scha¨fer (2012) focus their attention on a specific design change; namely, the
possibility of increasing the number of events from d1,2 to d
∗
1,2 by extending the follow-up period.
They assume that Y := (X1, X2) \X int1 and propose the second-stage decision function
ψxint1 (Y ) = 1
[
2S1,2(T
∗
1,2)/
{
D1,2(T
∗
1,2)
}1/2 ≥ b∗] , (7)
where T ∗1,2 := min
{
t : D1,2(t) = d
∗
1,2
}
and b∗ is a cutoff value that must be determined. Ideally,
one would like to choose b∗ such that EH0(ψXint1 | X int1 = xint1 ) = EH0(ϕ | X int1 = xint1 ), as this would
ensure that
EH0(ψXint1 ) = EH0
{
EH0
(
ψXint1 | X int1
)}
= EH0
{
EH0
(
ϕ | X int1
)}
= EH0(ϕ) = α, (8)
i.e., the overall procedure controls the type I error rate at level α. Unfortunately, this approach
is not directly applicable in a survival trial where X int1 contains short-term data from first-stage
patients surviving beyond T int. This is because it is impossible to calculate EH0(ϕ | X int1 = xint1 )
and EH0(ψXint1 | X int1 = xint1 ), owing to the unknown joint distribution of survival times and the
secondary/safety endpoints already observed at the interim analysis, c.f. Section 2.3. Irle and
Scha¨fer (2012) get around this problem by conditioning on additional variables; namely, S1(T1,2)
and S1(T
∗
1,2). Choosing ψxint1 such that
EH0
{
ψXint1 | X int1 = xint1 , S1(T1,2) = s1, S1(T ∗1,2) = s∗1
}
= EH0
{
ϕ | X int1 = xint1 , S1(T1,2) = s1, S1(T ∗1,2) = s∗1
}
ensures that EH0(ψXint1 ) = α following the same argument as (8).
Irle and Scha¨fer (2012) show that, asymptotically,
EH0
{
ϕ | X int1 = xint1 , S1(T1,2) = s1, S1(T ∗1,2) = s∗1
}
= EH0 {ϕ | S1(T1,2) = s1}
and
EH0
{
ψXint1 | X int1 = xint1 , S1(T1,2) = s1, S1(T ∗1,2) = s∗1
}
= EH0
{
ψxint1 | S1(T ∗1,2) = s∗1
}
.
In each case, calculation of the right-hand-side is facilitated by the asymptotic result that, assuming
equal allocation under the null hypothesis,(
S1(t)
S1,2(t)− S1(t)
)
∼ N
((
0
0
)
,
(
D1(t)/4 0
0 {D1,2(t)−D1(t)} /4
))
, (9)
for t ∈ [0, T ], where T is sufficiently large such that all events of interest occur prior to T .
One remaining subtlety is that EH0
{
ψxint1 | S1(T ∗1,2) = s1
}
can only calculated at calendar time
T ∗1,2, where T
∗
1,2 > T
int. Determination of b∗ must therefore be postponed until this later time.
It is shown in Appendix A that ψXint1 = 1 if and only if Z > Φ
−1(1− α), where Z is defined as in
(1) with p1 defined as in (4), T1 defined as equal to T1,2, the second-stage p-value function defined
as
p2(Y ) = 1− Φ
[
2
{
S1,2(T
∗
1,2)− S1(T ∗1,2)
}
/
{
d∗1,2 −D1(T ∗1,2)
}1/2]
, (10)
and the specific choice of weights:
w1 = {D1(T1,2)/d1,2}1/2 and w2 = [{d1,2 −D1(T1,2)} /d1,2]1/2 . (11)
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Remark 1. In a sense, the Irle and Scha¨fer method can be thought of as a special case of the
Jenkins et al. method, with a clever way of implicitly defining the weights and the end of first-stage
follow-up, T1. It has two potential advantages. Firstly, the timing of the interim analysis need not
be prespecified – in theory, one is permitted to monitor the accumulating data and at any moment
decide that design changes are necessary. Secondly, if no changes to the design are necessary, i.e.,
the trial completes as planned at calendar time T1,2, then the original test (6) is performed. In
this special case, no data is “thrown away”.
Remark 2. From first glance at (7), it may appear that the data from first-stage patients,
accumulating after T1,2, is never “thrown away”. However, this data is still effectively ignored. We
have shown that the procedure is equivalent to a p-value combination approach where p1 depends
only on data available at time T1 := T1,2. In addition, the distribution of p2 is asymptotically
independent of the data from first-stage patients: note that S1,2(T
∗
1,2) − S1(T ∗1,2) and S2(T ∗1,2) are
asymptotically equivalent (Irle and Scha¨fer, 2012, remark 1). The procedure therefore fits our
description of a “patient-wise separation” design, c.f. Section 2.4, and the picture is the same
as in Figure 3. The first-stage patients have in effect been censored at T1,2, despite having been
followed-up for longer.
This fact has important implications for the choice of d∗1,2. If one chooses d
∗
1,2 based on conditional
power arguments, one should be aware that the effective sample size has not increased by d∗1,2−d1,2.
Rather, it has increased by d∗1,2− d1,2−
{
D1(T
∗
1,2)−D1(T1,2)
}
, which could be very much smaller.
Remark 3. A potential disadvantage of the Irle and Scha¨fer (2012) method is that it is not possible
to decrease the number of events (nor decrease the recruitment rate) at the interim analysis, as
one must observe at least d1,2 events (in the manner specified by the original design) to be able to
calculate the conditional error probability EH0 {ϕ | S1(T1,2)}.
In addition, one is not permitted to increase the recruitment rate following the interim analysis, nor
to prolong the recruitment period beyond that prespecified by the original design. In order to allow
such design changes, a small extension is necessary. While the conditional error probability remains
EH0 {ϕ | S1(T1,2)}, the second-stage data must be split into two parts, Y =
{
(X1, X2) \X int1 , Y +
}
,
where Y + consists of responses from an additional cohort of patients, not specified by the original
design (see Figure 4). The second-stage test (7) can be replaced with, e.g.,
ψxint1 (Y ) = 1
[
2S2,+(T2,+)/ {D2,+(T2,+)}1/2 ≥ b∗
]
,
where D2,+(T2,+) and S2,+(T2,+) are the observed number of events and the usual logrank score
statistic, respectively, based on the responses of all patients recruited post T int, and T2,+ :=
min {t : D2,+(t) = d2,+} for some d2,+ defined at time T int. Again, determination of b∗ must be
postponed until time max(T1,2, T2,+).
3.3 Effect of unspecified follow-up data
Continuing with the set up and notation of Section 3.1 (which we have shown also fits the Irle and
Scha¨fer (2012) method), the adaptive test statistic is
Z = w1Φ
−1(1− p1) + w2Φ−1(1− p2)
= 2w1S1(T1)/D1(T1)
1/2 + w2Φ
−1(1− p2). (12)
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Figure 4: Extension of the Irle and Scha¨fer approach to allow a prolonged recruitment period.
Suppose, however, that the trial continues until calendar time T ∗, where T ∗ > T1. Strictly speaking,
the data from first-stage patients – those patients recruited prior to T int – accumulating between
times T1 and T
∗ should be “thrown away”. In this section we will investigate what happens, in
a worst case scenario, if this illegitimate data is naively incorporated into Z. Specifically, we find
the maximum type I error associated with the test statistic
Z∗ = 2w1S1(T ∗)/D1(T ∗)1/2 + w2Φ−1(1− p2). (13)
Since in practice T ∗ depends on the interim data in a complicated way, the null distribution of
(13) is unknown. One can, however, consider properties of the stochastic process
Z(t) = 2w1S1(t)/D1(t)
1/2 + w2Φ
−1(1− p2), t ∈ [T1, Tmax] .
In other words, we consider continuous monitoring of the logrank statistic based on first-stage
patient data. The worst-case scenario assumption is that the responses on short-term secondary
endpoints, available at the interim analysis, can be used to predict the exact calendar time the
process Z(t) reaches its maximum. In this case, one could attempt to engineer the second stage
design such that T ∗ coincides with this timepoint, and the worst-case type I error rate is therefore
PH0
{
max
t≥T1
Z(t) > Φ−1(1− α)
}
. (14)
Although the worst-case scenario assumption is clearly unrealistic, (14) serves as an upper bound
on the type I error rate. It can be found approximately via standard Brownian motion results.
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Define the information time at calendar time t to be u = D1(t)/D1(T
max), and let S1(u) denote
the logrank score statistic based on first-stage patients, followed-up until information time u. It
can be shown that B(u) := 2S1(u)/ {D1(Tmax)}1/2 behaves asymptotically like a Brownian motion
with drift ξ := θ {D1(Tmax)/4}1/2 (Proschan et al., 2006, p. 101).
We wish to calculate
Pθ=0
{
max
t≥T1
Z(t) > Φ−1(1− α)
}
=
∫ 1
0
Pθ=0
[
1
max
u=u1
B(u) > u1/2w−11
{
Φ−1(1− α)− w2Φ−1(1− p2)
}]
dp2,
(15)
where u1 = D1(T1)/D1(T
max). While the integrand on the right-hand-side is difficult to evaluate
exactly, it can be found to any required degree of accuracy by replacing the square root stopping
boundary with a piecewise linear boundary (Wang and Po¨tzelberger, 1997). Some further details
are provided in Appendix B.
The two parameters that govern the size of (14) are w1 and u1. Larger values of w1 reflect an
increased weighting of the first-stage data, which increases the potential inflation. In addition, a
low value for u1 increases the window of opportunity for stopping on a random high. Figure 5
shows that for a nominal α = 0.025 level test, the worst-case type I error can be up to 15% when
u1 = 0.1 and w1 = 0.9. As u1 → 0 the worst-case type I error rate tends to 1 for any value of w1
(see, e.g., Proschan et al., 1992).
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Figure 5: Worst case type I error for various choices of weights and information fractions.
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4 Example
The upper bound on the type I error rate, as depicted in Figure 5, varies substantially across w1
and u1. The following example, simplified from Irle and Scha¨fer (2012), is intended to give an
indication of what can be expected in practice.
A randomized trial is set up to compare chemotherapy (C) with a combination of radiotherapy
and chemotherapy (E). The anticipated median survival time on C is 14 months. If E were to
increase the median survival time to 20 months then this would be considered a clinically relevant
improvement. Assuming exponential survival times, this gives anticipated hazard rates λC = 0.050
and λE = 0.035, and a target log hazard ratio of θR = − log(λE/λC) = 0.36. If the error rates for
testing H0 : θ = 0 against Ha : θ = θR are α = 0.025 (one-sided) and β = 0.2, the required number
of deaths (assuming equal allocation) is
d1,2 = 4
[{
Φ−1(1− α) + Φ−1(1− β)} /θR]2 ≈ 248.
If 8 patients per month are recruited at a uniform rate throughout an initial period of 40 months,
and the survival times of these patients are followed-up for an additional 20 months after the end
of this period, then standard sample size formulae (Machin et al., 1997, Section 9.2.3.) tell us we
can expect to observe around 250 deaths by the time of the final analysis.
Now imagine, as Irle and Scha¨fer (2012) did, that an interim look is performed after 60 deaths,
observed 23 months after the start of the trial. At this point in time, 190 patients have been
recruited. Based on the interim results, it is decided to increase the total required number of
events from d1,2 to d
∗
1,2.
At the time of the 248th death, i.e., the originally planned study end T1,2, suppose we observe
that 170 of these deaths have come from patients recruited prior to the interim look. We have our
weights (11),
w1 = (170/248)
1/2 and w2 = (78/248)
1/2.
At this point we make a note of the standardized first-stage logrank score statistic S1(T1) :=
S1(T1,2) and hence p1 from (4), and continue to follow-up survival times until a total of d
∗
1,2 deaths
have been observed. Once these additional deaths have been observed, p2 can be found from (10),
and combined with p1 to give the adaptive test statistic (1).
Notice that w1 = (170/248)
1/2 and, ignoring any potential censoring, u1 = D1(T1)/D1(T
max) =
170/190. In this case a naive application of the test statistic (13) leads to an upper bound on the
type I error rate of 0.040. The inflation is not enormous, owing to the relatively slow recruitment
rate, but it is not hard to imagine more worrying scenarios.
Suppose, for example, that the trial design called for 48 patients to be recruited per month for
12 months, with 8 months of additional follow-up. Further suppose that an interim analysis took
place 6 months into the trial, by which time 288 patients had been recruited, and a decision was
made to increase the total number of events. Given the anticipated λC and λE, a plausible scenario
is that 147 of the first 248 events come from first-stage patients, implying that w1 = (147/248)
1/2
and u1 = 147/288. This gives an upper bound (14) of 0.066.
4.1 An alternative level-α test
A possible rationale for using (13), instead of (12), is that the final test statistic takes into account
all available survival times, i.e., does not ignore any data. If one is unprepared to give up the
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guarantee of type I error control, an alternative test can be found by increasing the cut-off value
for Z∗ from Φ−1(1− α) to k∗ such that∫ 1
0
Pθ=0
[
1
max
u=u1
B(u) > u1/2w−11
{
k∗ − w2Φ−1(1− p2)
}]
dp2 = α
This will, of course, have a knock on effect on power. Table 1 gives an impression of how much
the cutoff is increased from 1.96 when α = 0.025 (one sided).
Table 1: Cutoff values for corrected level-0.025 test.
u1
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
0.1 2.29 2.25 2.21 2.19 2.16 2.13 2.11 2.08 2.04
0.2 2.41 2.35 2.31 2.27 2.23 2.20 2.16 2.12 2.07
0.3 2.50 2.43 2.38 2.34 2.30 2.25 2.21 2.16 2.10
0.4 2.58 2.50 2.44 2.39 2.34 2.30 2.25 2.19 2.12
w1 0.5 2.64 2.56 2.49 2.44 2.38 2.33 2.27 2.21 2.14
0.6 2.70 2.60 2.53 2.47 2.42 2.36 2.30 2.23 2.15
0.7 2.74 2.64 2.57 2.51 2.45 2.39 2.33 2.26 2.17
0.8 2.79 2.68 2.60 2.54 2.48 2.41 2.35 2.28 2.18
0.9 2.83 2.72 2.64 2.57 2.50 2.43 2.37 2.29 2.19
In assessing the effect on power, at least four probabilities appear relevant:
A. Pθ=θR
[
2w1S1(T1)/ {D1(T1)}1/2 + w2Φ−1(1− p2) > Φ−1(1− α)
]
.
B. Pθ=θR
[
2w1S1(T1)/ {D1(T1)}1/2 + w2Φ−1(1− p2) > k∗
]
.
C. Pθ=θR
[
2w1S1(T
max)/ {D1(Tmax)}1/2 + w2Φ−1(1− p2) > k∗
]
.
D. Pθ=θR {maxt≥T1 Z(t) > k∗}.
Power definition A corresponds to the “correct” adaptive test. B can be thought of as a lower
bound on the power of the alternative level-α test, where one conscientiously specifies the increased
cutoff value k∗ (in anticipation of unpredictable end of first-stage follow-up), but it then turns out
that the trial finishes at the prespecified time point anyhow, i.e., T ∗ = T1. Definition C can
be thought of as the power of the alternative test if the trial is always prolonged such that all
first-stage events are observed. Definition D, on the other hand, can be interpreted as the power
of the alternative level-α test, taken at face value. In other words, assuming that one takes the
opportunity to stop follow-up of first-stage patients when Z(t) is at its maximum. This can be
calculated using the same techniques as in Section 3.3.
Figure 6 shows the power of the trial described in Example 4, according to A-D. The power has
been evaluated conditional on p2, as this is a random variable common to all four definitions. The
increased cutoff value of the alternative level-α test leads to a sizeable loss of power if the trial
completes as planned. In the second scenario at least, the loss of power can be more than made up
12
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Figure 6: Conditional power as defined by A (thin line), B (medium line), C (thick line) and Dy
(dashed line) given p2, under the two scenarios described in Example 4. Scenario (a): D1(T1) = 170,
D1(T
max) = 190, w1 = (170/248)
1/2 and θR = 0.36. Scenario (b): D1(T1) = 147, D1(T
max) = 288,
w1 = (147/248)
1/2 and θR = 0.36.
for when the trial is prolonged. However, if there is an a-priori reasonable probability of prolonging
the trial, then one could just start with a larger sample size/ required number of events.
In general, the differences between power definitions A-D will tend to follow the same pattern
as in Figure 6. The degree to which they differ will depend on w1, D1(T1), D1(T
max) and θR.
Intuitively, larger w1 and smaller u1 will lead to a greater loss of power going from A to B, but
with a greater potential gain in power going from B to C (or D). The actual gain in power from
B to C (or D) will be greatest for large values of θR
4.2 Diverging hazard rates
Consider the second trial design in Section 4, where recruitment proceeds at a uniform rate of 48
patients per month for 12 months, with 8 months of additional follow-up. Suppose, however, that
the true hazard rates are not proportional. Rather, hE(τ) = 0.04 and h
−1
C (τ) = 0.04
−1 − 0.6τ
for τ ∈ (0, 30), where τ denotes the time in calendar months since randomization. Simulating a
realization of this trial, 295 patients are recruited in the first six months, by which time there have
been 18 deaths on C, and 15 deaths on E. Suppose that at this point it is decided to increase the
target number of events from d1,2 = 248 to d
∗
1,2 = 350. At time T1,2, the number of deaths from
first-stage patients – those patients recruited in the first six months – is D1(T1,2) = 151, such that
w1 = (151/248)
1/2, u1 = 151/295 and k
∗ = 2.41. The logrank score statistics based on first-stage
patients is S1(T1,2) = 7.6, giving a first-stage p-value (4) of
p1 = 1− Φ
{
2(7.6)/1511/2
}
= 0.108
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and a conditional error probability (6) of EH0 {ϕ | S1(T1,2) = 7.6} = 0.213, using (9).
The survival data at time T ∗1,2, occurring approximately 26 months into the trial, is plotted in
Figure 7. On the left-hand-side, all survival times have been included in the Kaplan-Meier curves.
There is an obvious divergence in the survival probabilities on the two treatments. However, the
test decision of Irle and Scha¨fer (2012) may only use the data as depicted on the right-hand-side,
where the survival times of first-stage patients have been censored at time T1,2. They are liable to
reach an inappropriate conclusion. In this case, 199 out of the first 350 events are from patients
recruited in the first six months, and the logrank score statistic based on first-stage patients is
S1(T
∗
1,2) = 16. The new cutoff value b
∗ must be found to solve
EH0
{
ψxint1 | S1(T ∗1,2) = 16
}
= PH0
{
2S1,2(T
∗
1,2)/350
1/2 ≥ b∗ | S1(T ∗1,2) = 16
}
= 0.213,
which gives b∗ = 2.76, using (9). The logrank statistic based on all survival times at T ∗1,2 is
S1,2(T
∗
1,2) = 25 and the test decision is
ψxint1 = 1
{
2(25)/3501/2 ≥ 2.76} = 0,
i.e., one cannot reject the null hypothesis. As shown in Section 3.2, the same decision could have
been reached by finding the second-stage p-value (10)
p2 = 1− Φ
[
2 {25− 16} /(350− 199)1/2] = 0.071,
computing the adaptive test statistic (1),
Z = w1Φ
−1(1− p1) + w2Φ−1(1− p2) = 1.88,
and comparing with Φ−1(1− α) ≈ 1.96. The number of events that have been ignored in making
this decision is D1(T
∗
1,2)−D1(T1,2) = 48.
If, on the other hand, one had prespecified the alternative test of Section 4.1, then one would be
permitted to replace Φ−1(1− p1) in the adaptive test statistic with the value of the standardized
logrank statistic at time T ∗1,2. In this case one would be able to reject the null hypothesis, as
Z(T ∗1,2) = 2w1S1(T
∗
1,2)/D1(T
∗
1,2)
1/2 + w2Φ
−1(1− p2) = 2.69 > k∗.
5 Discussion
Adaptive design methodology – developed over the past two decades to cope with mid-study
protocol changes in confirmatory clinical trials – is becoming increasingly accepted by regulatory
agencies (Elsaesser et al., 2013). It is therefore unfortunate that the important case of time-to-
event data is not easily handled by the standard theory. As far as survival data are concerned,
all proposed solutions have limitations and there is a trade-off between strict type I error control,
power, flexibility, the use of all interim data to substantiate interim decision making, and the use
of all available data in making the test decision at the final analysis.
The proposed solutions of Irle and Scha¨fer (2012) and Jenkins et al. (2011) offer strict type I error
control and allow full use of the interim data. The Jenkins et al. (2011) method allows one to
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Figure 7: Kaplan-Meier plots corresponding to the hypothetical trial described in Section 4.2
based on (a) all available survival times at T ∗1,2, and (b) with first-stage and second-stage patients
censored at T1,2 and T
∗
1,2, respectively.
change the recruitment rate at the interim analysis – something that is disallowed by Irle and
Scha¨fer (2012), where one is only permitted to increase the observation time. On the other hand,
Irle and Scha¨fer (2012) is more flexible in the sense that the timing of the interim analysis need
not be prespecified. In both cases, the final test decision only depends on a subset of the recorded
survival times, i.e., part of the observed data is ignored. This is usually deemed unacceptable by
regulators. Furthermore, it is the long-term data of patients recruited prior to the interim analysis
that is ignored, such that more emphasis is put on early events in the final decision making. This
neglect becomes egregious when there is specific interest in learning about the long-term parts of
the survival curves.
We have therefore proposed an alternative procedure which offers the same type I error control and
flexibility as Jenkins et al. (2011) and Irle and Scha¨fer (2012), in addition to a final test statistic
that takes into account all available survival times. However, in order to achieve this, a worst-case
adjustment is made a-priori in the planning phase. If no design modifications are performed at
the interim analysis, the worst-case critical boundary must nevertheless be applied. This results
in a loss of power.
Methods based on the independent increments assumption have been only briefly mentioned in
Section 2.3. They suffer from the limitation that decision makers must be blinded to short-term
data at the interim analysis. On the other hand, subject to this blinding being imposed, the type
I error rate is controlled and the final test decision is based on all available survival times. This
could therefore be a viable option in situations where the short-term data is sparse or relatively
uninformative. Yet another option, if one is prepared to give up strict type I error control, is
simply to use the usual logrank test at the final analysis. The true operating characteristics of
such a procedure are unclear, owing to the complex dependence on the interim data.
Our alternative level-α test may have practical applications in multi-arm survival trials (Jaki and
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Magirr, 2013) and adaptive enrichment designs. In this case, one must take great care in applying
the methodology of Jenkins et al. (2011) or Irle and Scha¨fer (2012). One specific issue is that
dropping a treatment arm will affect recruitment rates on other arms. Also, for treatment regimes
that have to be given continuously over a period of time, it would be unethical to keep treating
patients on treatment arms that have been dropped for futility. This may affect the timing of
analyses on other arms. Incorporating some flexibility into the end of patient follow-up could
confer advantages here. More research is needed in this area.
The usefulness of performing design modifications has to be thoroughly assessed on a case-by-case
basis in the planning phase. Interim data may be highly variable, and the interim survival results
may be driven mainly by early events. Consequently, the interim data may be too premature to
allow a sensible interpretation of the whole survival curves and may not be a reliable basis for
adaptations.
In this respect, the best advice might be to thoroughly assess the characteristics of adaptive trial
designs in comparison with more standard approaches, and to plan for adaptations only in settings
where the advantages are compelling. If in the planning phase there is a strong likelihood that
the number of patients will need to be increased, or the observation time extended, our analysis
has shown that there is no uniformly best design. All proposals to implement adaptive survival
designs have their limitations. If the main objective is strict type I error control when using all
data, then our proposal should be considered as a valid option.
Appendix A
Connection between conditional error and combination test
The cut-off b∗ satisfies
EH0 {ϕ | S1(T1,2) = s1} = PH0
{
2S1,2(T
∗
1,2)/(d
∗
1,2)
1/2 ≥ b∗ | S1(T ∗1,2) = s∗1
}
= PH0
[
2
{
S1,2(T
∗
1,2)− S1(T ∗1,2)
}
/
{
d∗1,2 −D1(T ∗1,2)
}1/2 ≥ c∗ | S1(T ∗1,2) = s∗1] ,
which implies that c∗ = Φ−1 [1− EH0 {ϕ | S1(T1,2) = s1}], using (9). Therefore,
ψXint1 = 1⇔ 2S1,2(T ∗1,2)/(d∗1,2)1/2 ≥ b∗
⇔ 2{S1,2(T ∗1,2)− S1(T ∗1,2)} /{d∗1,2 −D1(T ∗1,2)}1/2 ≥ c∗
⇔ Φ−1(1− p2) ≥ Φ−1 [1− EH0 {ϕ | S1(T1,2) = s1}]
⇔ p2 ≤ EH0 {ϕ | S1(T1,2) = s1} .
The conditional error probability, EH0 {ϕ | S1(T1,2) = s1}, can be found from the joint distribution
(9) at calendar time T1,2. Omitting the argument T1,2 from S1, S1,2, D1 and D1,2:
EH0 {ϕ | S1 = s1} = PH0
{
2S1,2/(D1,2)
1/2 > Φ−1(1− α) | S1 = s1
}
= PH0
[
2(S1,2 − S1)/(D1,2 −D1)1/2 > Φ−1(1− α) {D1,2/(D1,2 −D1)}1/2
−2S1/(D1,2 −D1)1/2 | S1 = s1
]
= 1− Φ
[
Φ−1(1− α) {D1,2/(D1,2 −D1)}1/2 − Φ−1(1− p1) {D1/(D1,2 −D1)}1/2
]
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and therefore p2 ≤ EH0 {ϕ | S1(T1,2) = s1} if and only if
{D1(T1,2)/d1,2}1/2 Φ−1(1− p1) + [{d1,2 −D1(T1,2)} /d1,2]1/2 Φ−1(1− p2) ≥ Φ−1(1− α).
Appendix B
Computation of (14)
For simplicity, consider replacing the square root boundary in (15) with a linear boundary. Con-
ditional on p2, our problem is to find Pθ=0 {B(u) < au+ b, u1 < u ≤ 1}, where a and b are found
by drawing a line through
u1, u
1/2
1 w
−1
1
{
Φ−1(1− α)− w2Φ−1(1− p2)
}
and
1, w−11
{
Φ−1(1− α)− w2Φ−1(1− p2)
}
.
For constants a, b and c, with b, c > 0, Siegmund (1986) shows that
Pθ=0 {B(u) ≥ au+ b, for some 0 < u ≤ c | W (c) = x} = exp {−2b(ac+ b− x)/c}
and integrating over x gives
Pθ=0 {B(u) < au+ b, u ≤ c} = Φ
{
(ac+ b)/c1/2
}− exp(−2ab)Φ{(ac− b)/c1/2} . (16)
Therefore, conditioning on the value of B(u1),
Pθ=0 {B(u) < au+ b, u1 < u ≤ 1} =
∫ au1
−∞
Pθ=0 {B(u) < au+ b, u1 < u ≤ 1 | B(u1) = x} dPu1(x; 0)
=
∫ au1
−∞
Pθ=0 {B(u+ u1)− x
< a(u+ u1) + b− x, 0 < u ≤ 1− u1 | B(u1) = x} dPu1(x; 0)
=
∫ au1
−∞
Pθ=0 {B(v) < av + au1 + b− x, 0 < v ≤ 1− u1} dPu1(x; 0)
=
∫ au1
−∞
Φ
{
a+ b− x
(1− u1)1/2
}
− exp {−2a(au1 + b− x)}Φ
{
a(1− 2u1)− b+ x
(1− u1)1/2
}
dPu1(x; 0).
Greater accuracy can be achieved by replacing the square root boundary with a piece-wise linear
boundary, in which case one must condition on the value of the Brownian motion at each of the
cut-points (Wang and Po¨tzelberger, 1997).
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